Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W-135, and Y conjugate vaccine + influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
meningococcal vaccine GSK134612 + Fluarix refers to the co-administration of GSK's quadrivalent meningococcal conjugate vaccine (GSK134612, later branded as Nimenrix) and its seasonal influenza vaccine (Fluarix). GSK134612 is a conjugate vaccine consisting of Neisseria meningitidis capsular polysaccharides from serogroups A, C, W-135, and Y, each covalently linked to a tetanus toxoid carrier protein. Fluarix is an inactivated, split-virion influenza vaccine containing antigens from seasonal influenza A and B strains. This combination was primarily studied in clinical trials (such as NCT00453986) to evaluate the safety, immunogenicity, and lack of interference when the two vaccines are administered simultaneously to adults.
- Brand names
- Nimenrix
- Other names
- MenACWY-TT + Fluarixmeningococcal vaccine GSK134612 + Fluarix
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)HA (Hemagglutinin)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, W-135, and Y conjugate vaccine + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W-135, and Y conjugate vaccine + influenza vaccine.